Literature DB >> 15312243

Intracellular machinery for matrix degradation in bone-resorbing osteoclasts.

Jukka Vääräniemi1, Jussi M Halleen, Katja Kaarlonen, Hannele Ylipahkala, Sari L Alatalo, Göran Andersson, Helena Kaija, Pirkko Vihko, H Kalervo Väänänen.   

Abstract

UNLABELLED: In osteoclasts, TRACP co-localized with cathepsin K in transcytotic vesicles and was activated by cathepsin K in vitro, suggesting that TRACP may degrade organic matrix components in transcytotic vesicles in an event regulated by cathepsin K.
INTRODUCTION: TRACP is an enzyme with unknown biological function. In addition to its phosphatase activity, TRACP is capable of generating reactive oxygen species (ROS). Bone-resorbing osteoclasts contain large amounts of TRACP, and transgenic animal models suggest that TRACP has a role in bone resorption. Osteoclasts resorb bone by secreting acid and lysosomal enzymes such as cathepsin K into an extracellular resorption lacuna between the cell membrane and bone surface. Matrix degradation products are then endocytosed, transcytosed, and secreted through a functional secretory domain in the basolateral membrane facing bone marrow.
MATERIALS AND METHODS: We have studied intracellular localization of TRACP in osteoclasts with antibodies against various known endosomal and lysosomal proteins using confocal microscopy. We also studied co-localization of TRACP with cathepsin K and endocytosed bone matrix components and the effect of cathepsin K digestion on the ROS generating activity of TRACP in vitro.
RESULTS: Double-staining experiments of TRACP with endosomal and lysosomal markers showed that, although some endosomal staining was detected, TRACP was not present in lysosomes. However, TRACP was present in transcytotic vesicles, where it co-localized with cathepsin K. Cathepsin K digestion of TRACP in vitro increased the phosphatase activity by 5.6-fold and the ROS generating activity by 2.0-fold.
CONCLUSIONS: These results suggest that cathepsin K may activate the ROS-generating activity of TRACP in transcytotic vesicles of resorbing osteoclasts, the ROS being targeted to finalize degradation of organic bone matrix components during their transcytosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312243     DOI: 10.1359/JBMR.040603

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  35 in total

1.  Isolation and transcription profiling of purified uncultured human stromal stem cells: alteration of gene expression after in vitro cell culture.

Authors:  Andrew C Boquest; Aboulghassem Shahdadfar; Katrine Frønsdal; Olafur Sigurjonsson; Siv H Tunheim; Philippe Collas; Jan E Brinchmann
Journal:  Mol Biol Cell       Date:  2005-01-05       Impact factor: 4.138

2.  Polarization and secretion of cathepsin K precede tartrate-resistant acid phosphatase secretion to the ruffled border area during the activation of matrix-resorbing clasts.

Authors:  Karin Hollberg; Joakim Nordahl; Kjell Hultenby; Silwa Mengarelli-Widholm; Göran Andersson; Finn P Reinholt
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

3.  Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption.

Authors:  Nathan J Pavlos; Jiake Xu; Dietmar Riedel; Joyce S G Yeoh; Steven L Teitelbaum; John M Papadimitriou; Reinhard Jahn; F Patrick Ross; Ming H Zheng
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

4.  Functional analysis of monocyte MHC class II compartments.

Authors:  Allyson Bunbury; Ilaria Potolicchio; Radhashree Maitra; Laura Santambrogio
Journal:  FASEB J       Date:  2008-09-24       Impact factor: 5.191

5.  Immune and inflammatory pathways are involved in inherent bone marrow ossification.

Authors:  Umut Atakan Gurkan; Ryan Golden; Vipuil Kishore; Catherine P Riley; Jiri Adamec; Ozan Akkus
Journal:  Clin Orthop Relat Res       Date:  2012-09       Impact factor: 4.176

6.  Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo.

Authors:  Kim Henriksen; Jeppe Gram; Pernille Høegh-Andersen; Rune Jemtland; Thor Ueland; Morten H Dziegiel; Sophie Schaller; Jens Bollerslev; Morten A Karsdal
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

7.  Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.

Authors:  Le T Duong
Journal:  Bonekey Rep       Date:  2012-05-02

8.  Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.

Authors:  Cristiano A F Zerbini; Michael R McClung
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

9.  Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.

Authors:  Anita V Neutzsky-Wulff; Mette G Sørensen; Dino Kocijancic; Diana J Leeming; Morten H Dziegiel; Morten A Karsdal; Kim Henriksen
Journal:  BMC Musculoskelet Disord       Date:  2010-06-01       Impact factor: 2.362

10.  Human macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processes.

Authors:  Natasha Barascuk; Helene Skjøt-Arkil; Thomas C Register; Lise Larsen; Inger Byrjalsen; Claus Christiansen; Morten A Karsdal
Journal:  BMC Cardiovasc Disord       Date:  2010-04-21       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.